Molecular Formula | C26H28N2 |
Molar Mass | 368.51 |
Density | 1.1818 (rough estimate) |
Melting Point | 117-120°C |
Boling Point | 488.83°C (rough estimate) |
Water Solubility | 0.75g/L(temperature not stated) |
Solubility | Soluble in chloroform at 50mg/ml |
Appearance | powder |
Color | white |
Merck | 14,2305 |
pKa | pKa 7.47(H2O t=25.0 ) (Uncertain) |
Storage Condition | Sealed in dry,2-8°C |
Refractive Index | 1.7620 (estimate) |
Physical and Chemical Properties | Chemical properties of brain prezine hydrochloride, C26H28N2 · 2HCI,[7002-58-6], melting point 192 °c, solubility in water 2mg/100ml. |
Use | Uses long-acting multi-functional vasoconstrictor antagonist, can expand blood vessels, improve blood circulation, prevent vascular embrittlement, can be used for the treatment of cerebrovascular diseases, such as cervical vertigo caused by Head Pain, dizziness Sleep Initiation and Maintenance Disorders, memory loss, hemiplegia, limb numbness, weakness, slurred speech and other symptoms also have curative effect. |
In vitro study | Cinnarizine inhibits melanogenesis in B16 cells in a dose-dependent manner (non-cytotoxic concentrations) and is also an antagonist of histamine receptors. |
In vivo study | In female PK-KO mice, cinnarizine induced behavioral changes such as baldness, buccal and lingual dyskinesia, and decreased motor activity, but not in wild-type mice. In PK-KO mice, with high striatal dopamine levels and dopamine metabolism (despite decreased protein tyrosine hydroxylase),cinnarizine treatment blocks dopamine receptors and enhances dopamine release, further enhance the metabolism of dopamine. |
Hazard Symbols | Xn - Harmful |
Risk Codes | R20/22 - Harmful by inhalation and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. R42/43 - May cause sensitization by inhalation and skin contact. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36 - Wear suitable protective clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 2 |
RTECS | TL3430000 |
Toxicity | LD50 oral in rat: > 6500mg/kg |
generated element , Dong Zhao , Li Yansheng , Wanqi , Full week , Qiao Xiangyang
Abstract:
objective: to investigate the efficacy and safety of flunarizine hydrochloride in the preventive treatment of Head Pain. Methods: An open study, 2120 cases of partial Head Pain patients daily oral flunarizine hydrochloride 5~10mg, treatment time for 12 weeks, at the beginning of treatment and 4 weekend, 8 weekend, at the end of 12 weeks, the degree of Head Pain, frequency, dose, occurrence of adverse events, and blood pressure were recorded. Results: at the end of 4 weeks, 8 weeks and 12 weeks after treatment, the degree of Head Pain was significantly reduced (all P0.05), and the frequency was significantly reduced (all P0.05), the dosage of flunarizine hydrochloride was also significantly reduced (all P0.05), no serious adverse events were found, and there was no significant change in blood pressure before and after treatment (all P0.05). Conclusion: flunarizine hydrochloride is a safe and effective drug for prophylactic treatment of Head Pain.
Key words:
migraine calcium channel flunarizine hydrochloride
DOI:
10.3969/j.issn.1006-1959.2016.36.275
cited:
year:
2016
Abstract:
62 patients with Meniere's disease were divided into two groups. 34 cases (age 58 ± s 14 a) were treated with oral Di'ao xinxuekang 200 mg,tid;28 cases (age 53±10a) were treated with flunarizine 5 mg,bid (niacin 100 mg tid or vinpocetine tablets 5 mg tid), the effective rate of 7 d.2 group was 94% and 82%(P>0.05). Diao xinxuekang took effect quickly, the symptoms disappeared early, no adverse reactions, suggesting that the drug has a good effect on Meniere's disease.
Key words:
Diao xinxuekang Meniere's disease flunarizine saponins
meeting name:
National Symposium on clinical evaluation of traditional Chinese medicine in treating cardiac encephalopathy
meeting place:
Beijing, China
cited:
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
Peripheral vasodilators | Cinnarizine is a piperazine calcium channel blocker, which belongs to peripheral vasodilators. Also known as cinnamon, cinnamon, cinnamon, cinnamon, naoyizine, white or white crystal or crystalline powder, odorless, almost tasteless. Several insoluble in water, soluble in boiling ethanol, easily soluble in chloroform or benzene. Cinnarizine has a dilating effect on vascular smooth muscle, and has an antagonistic effect on various vasoconstricting substances such as serotonin, epinephrine, bradykinin, and vasopressin, and can relieve vasospasm. Its antispasmodic effect is stronger than papaverine, and the sedative effect is not obvious. This product can significantly increase cerebral blood flow, can significantly improve cerebral circulation and coronary circulation, and has a long duration of action, and has an inhibitory effect on various vasoactive substances, which can relieve vasospasm and prevent vascular embrittlement. It can increase coronary blood flow and cardiac output without affecting heart rate and oxygen consumption. Intravenous injection of this product can temporarily reduce blood pressure, but oral administration has no such effect. In addition, this product also has the effect of preventing vascular embrittlement and antihistamine. it takes effect within 30 minutes after oral administration, and the blood drug concentration peaks after 3-7 hours, and the effect lasts for 4 hours. The half-life of blood drug concentration is 3~24 hours. Clinically, cinnamrizine is mainly used to treat cerebrovascular disorders and peripheral vascular diseases such as cerebral embolism, cerebral thrombosis, cerebral arteriosclerosis, cerebral circulation insufficiency caused by hypertension, cerebral hemorrhage and subarachnoid hemorrhage recovery period, brain trauma sequelae. It is also effective for mental neuropathy and coronary arteriosclerosis caused by cerebral circulation disorders. It can also be used to treat nausea, vomiting and motion sickness caused by inner ear vertigo and other labyrinthine disorders. the main adverse reactions of cinnarizine are: occasional drowsiness, rash, gastrointestinal reactions, fever or dizziness, intravenous injection can make blood pressure drop temporarily; pregnant women should use it with caution; intracranial hemorrhage and acute cerebral infarction should not be used. |
biological activity | Cinnarizine (Stugeron, Dimitronal, Stutgin, Cinarizine) are piperazine drug derivatives, antihistamines and calcium channel blockers. |
Target | Value |
Use | Long-acting multifunctional vasoconstriction antagonist can dilate blood vessels, improve blood circulation, prevent vascular embrittlement, and can be used to treat cerebrovascular diseases. Headache, dizziness, insomnia, memory loss, hemiplegia, limb numbness and weakness, slurred speech and other symptoms caused by cervical vertigo are also effective. |
Production method | Diphenylmethyl piperazine is prepared from anhydrous piperazine and brominated diphenylmethane, and then condensed with benzene propylene chloride. Diphenylmethane is heated under light, bromine is added dropwise, and the temperature is kept at 130 ℃ for 1h to obtain brominated diphenylmethane, C13H11Br,[776-74-9], melting point 45 ℃. Bromodiphenylmethane is added dropwise to piperazine toluene solution, stirred at 80-90 ℃ for 3 hours, cooled and washed with water, then extracted with 10% dilute hydrochloric acid, alkalized and precipitated the acid layer, filtered and dried to obtain diphenylmethyl piperazine. Dissolve it in 95% ethanol, add sodium carbonate, add benzyl propylene chloride dropwise at about 65 ℃, after dropping, heat and reflux for 4 hours, filter while hot, place the filtrate into the liquid, precipitate crystallization, filter, obtain crude naoyizine, and refine to obtain finished products with melting point of 117-119 ℃. Based on diphenylmethane, the total yield is 48.2%. |